Clinical characteristics and prognosis of patients with ulcerative colitis that shows rectal sparing at initial diagnosis

Table 1 Clinical characteristics of rectal sparing ulcerative colitis at diagnosis

	Rectal spring UC at diagnosis (n = 24)
Age (yr)	35.8 ± 11.0
Sex (male:female)	19:5
Disease distribution
Extensive colitis (E3) with rectal sparing	16 (66.7%)
Left-sided colon (E2) with rectal sparing	8 (33.3%)
Initial Diagnosis
IBD-U	8 (33.3%)
Infectious colitis	7 (29.2%)
UC	7 (29.2%)
Nonspecific	2 (8.3%)
Symptom duration	2 mo (2 wk to 60 mo)
Laboratory findings
WBC (count/mm3)	6475.9 ± 2273.4
ESR (mm/h)	17.4 ± 13.9
CRP (mg/dL)	0.4 ± 0.7
p-ANCA positive	4 (16.7%)
Follow-up endoscopy (follow-up period median 9 yr, 5-15 yr)
Persistence of rectal sparing	2 (8.3%)
Appearance of proctitis	22 (91.7%)

UC: Ulcerative colitis; IBD: Inflammatory bowel disease; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; ANCA: Anti-neutrophil cytoplasmic antibodies; WBC: White blood cell.

Table 2 Summarized clinical history of ulcerative colitis patients who used biologics in both study and control group

No.	Age at diagnosis	Sex	Initial endoscopic finding	No. of systemic steroid use	Indication for biologics	History of biologics	Colectomy
1	21	F	RS	4	Steroid dependent	infliximab	-
2	30	F	RS	2	Steroid refractory	Infliximab (failed)	+
3	31	F	RS	9	Steroid dependent	golimumab	-
4	35	M	RS	2	Steroid refractory	Infliximab (failed)	+
5	15	F	RI	3	Steroid refractory	golimumab
6	22	F	RI	1	Steroid refractory	Infliximab (failed)	+
7	20	F	RI	7	Steroid dependent	golimumab topacitinib	-
8	33	M	RI	4	Steroid refractory	infliximab	-
9	34	M	RI	2	Steroid refractory	Infliximab (failed)	+
10	35	M	RI	4	Steroid refractory	golimumab	-
11	39	M	RI	3	Steroid refractory	golimumab	-
12	41	F	RI	4	Steroid dependent	golimumab	-
13	44	M	RI	5	Steroid refractory	golimumab	-
14	48	M	RI	2	Steroid refractory	golimumab	-

RS: Rectal sparing; RI: Rectal involvement.

Table 3 Clinical prognosis of ulcerative colitis with rectal sparing versus without rectal sparing (control)

			Rectal sparing UC (n = 24)	Control (n = 72)	P value
Age			35.8 ± 11.0	36.6 ± 10.6	Matched
Sex (male:female)			19:5	57:15	Matched
Disease extent (E2/E3)			8/16	24/48	Matched
Follow-up period (mo)			103.4 ± 41.3	109.4 ± 41.6	0.5
Clinical outcomes
	Use of systemic corticosteroid				0.77
		3-yr cumulative rate	35.3%	34.7%
		5-yr cumulative rate	46.0%	41.8%
		10-yr cumulative rate	53.8%	61.1%
	Use of biologics		4 (16.7%)	10 (13.9%)	0.74
		Hospitalization	4 (16.7%)	16 (22.2%)	0.77
		Colectomy	2 (8.3%)	2 (2.8%)	0.26

UC: Ulcerative colitis.